Investors
Analyst Coverage
Research analysts have, from time to time, published material commenting on BTG. Any opinions, estimates or forecasts regarding the Company's performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of the Company or its Management. You should, therefore, not place undue reliance on the content of any such analyst report or statement. The following analysts currently issue reports on us:
| Company | Analyst |
|---|---|
| Brewin Dolphin | James Hay |
| Daniel Stewart | Vadim Alexandre |
| Deutsche Bank | Richard Parkes, Jeremy Lai, Mark Clark |
| Edison Investment Research | Robin Davison |
| FinnCap | Keith Redpath |
| Jefferies | Philippa Gardner |
| J.P. Morgan Cazenove | James Gordon |
| Nomura Code | Gary Waanders |
| Panmure Gordon & Co | Savvas Neophytou |
| Peel Hunt | Paul Cuddon |
These reports cannot be obtained directly from us. Any reports issued may have become out of date following publication and should be read accordingly.
Retaining value
In October 2010 we regained US sales and marketing rights for our two critical care products, doubling revenues from these products and increasing our margins.
Investor contacts
We have a variety of different investor and shareholder contacts depending on the nature of your enquiry.